These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3207022)

  • 1. Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability.
    Kohlschütter A; Laabs R; Albani M
    Acta Paediatr Scand; 1988 Nov; 77(6):867-72. PubMed ID: 3207022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment.
    Santavuori P; Heiskala H; Autti T; Johansson E; Westermarck T
    Adv Exp Med Biol; 1989; 266():273-82. PubMed ID: 2486154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Follow-up of Spielmeyer-Vogt disease over 21 years].
    Hoppen T; Ferrari R; Kohout B; Löhr-Nilles C; Rister M
    Klin Padiatr; 1992; 204(2):111-4. PubMed ID: 1583849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.
    Augustine EF; Adams HR; Beck CA; Vierhile A; Kwon J; Rothberg PG; Marshall F; Block R; Dolan J; Mink JW;
    Dev Med Child Neurol; 2015 Apr; 57(4):366-71. PubMed ID: 25387857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis.
    Aberg LE; Bäckman M; Kirveskari E; Santavuori P
    Epilepsia; 2000 Oct; 41(10):1296-302. PubMed ID: 11051125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juvenile neuronal ceroid lipofuscinosis and education.
    von Tetzchner S; Fosse P; Elmerskog B
    Biochim Biophys Acta; 2013 Nov; 1832(11):1894-905. PubMed ID: 23470553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease).
    Ostergaard JR; Rasmussen TB; Mølgaard H
    Neurology; 2011 Apr; 76(14):1245-51. PubMed ID: 21464428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippocampal volumes in juvenile neuronal ceroid lipofuscinosis: a longitudinal magnetic resonance imaging study.
    Tokola AM; Salli EK; Åberg LE; Autti TH
    Pediatr Neurol; 2014 Feb; 50(2):158-63. PubMed ID: 24411222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical late infantile and juvenile forms of neuronal ceroid lipofuscinosis and their diagnostic difficulties.
    Wiśniewski KE; Zhong N; Kida E; Kaczmarski W; Kaczmarski A; Connell F; Brooks SS; Brown WT
    Folia Neuropathol; 1997; 35(2):73-9. PubMed ID: 9377079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile neuronal ceroid lipofuscinosis.
    Gulati S; Maheshwari R; Kabra M; Verma IC; Kalra V
    Indian J Pediatr; 2000 Sep; 67(9):689-91. PubMed ID: 11028125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cataract and glaucoma development in juvenile neuronal ceroid lipofuscinosis (batten disease).
    Nielsen AK; Drack AV; Ostergaard JR
    Ophthalmic Genet; 2015 Mar; 36(1):39-42. PubMed ID: 25365415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data.
    Cialone J; Augustine EF; Newhouse N; Adams H; Vierhile A; Marshall FJ; de Blieck EA; Kwon J; Rothberg PG; Mink JW
    J Inherit Metab Dis; 2011 Oct; 34(5):1075-81. PubMed ID: 21556831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vision loss as the presenting sign in juvenile neuronal ceroid lipofuscinosis.
    Bohra LI; Weizer JS; Lee AG; Lewis RA
    J Neuroophthalmol; 2000 Jun; 20(2):111-5. PubMed ID: 10870925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxysmal sympathetic hyperactivity in Juvenile neuronal ceroid lipofuscinosis (Batten disease).
    Ostergaard JR
    Auton Neurosci; 2018 Nov; 214():15-18. PubMed ID: 30072301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
    de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
    J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroencephalography in juvenile neuronal ceroid lipofuscinosis: visual and quantitative analysis.
    Larsen A; Sainio K; Aberg L; Santavuori P
    Eur J Paediatr Neurol; 2001; 5 Suppl A():179-83. PubMed ID: 11588993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep disturbance in patients with juvenile neuronal ceroid lipofuscinosis: a new application of the SCSB-method.
    Telakivi T; Partinen M; Salmi T
    J Ment Defic Res; 1985 Mar; 29 ( Pt 1)():29-35. PubMed ID: 4009701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mutation af Cln3 associated with delayed-classic juvenile ceroid lipofuscinois and autophagic vacuolar myopathy.
    Licchetta L; Bisulli F; Fietz M; Valentino ML; Morbin M; Mostacci B; Oliver KL; Berkovic SF; Tinuper P
    Eur J Med Genet; 2015 Oct; 58(10):540-4. PubMed ID: 26360874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive Treatment for Retinal Degeneration in Juvenile Neuronal Ceroid Lipofuscinosis (Juvenile Batten Disease).
    Drack AV; Mullins RF; Pfeifer WL; Augustine EF; Stasheff SF; Hong SD
    Ophthalmic Genet; 2015; 36(4):359-64. PubMed ID: 24547931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis.
    Aberg L; Kirveskari E; Santavuori P
    Epilepsia; 1999 Jun; 40(6):796-9. PubMed ID: 10368082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.